5 High Growth Stocks Insiders Are Buying

2. Kalaris Therapeutics, Inc. (NASDAQ:KLRS)

On July 6, 2026, Kalaris Therapeutics, Inc. (NASDAQ:KLRS) announced the appointment of Laurie Keating to its Board of Directors, effective August 1, 2026. In connection with Keating’s appointment, Morana Jovan-Embiricos is stepping down from the Board.

David Hallal, Chairman of the Kalaris Board of Directors, said Keating brings strategic, operational, and legal expertise across multiple therapeutic areas and development stages. Hallal also thanked Jovan-Embiricos for her service over the past year, noting her role in helping Kalaris advance TH103 and evolve as a public biotech company.

On June 15, 2026, TD Cowen analyst Tara Bancroft initiated coverage of Kalaris Therapeutics with a Buy rating and no price target. Bancroft said the company’s TH103 is a “differentiated” anti-VEGF by design through more potent VEGF inhibition and retinal retention. Bancroft added that early data in wet age-related macular degeneration suggest even a single dose can achieve competitive efficacy versus the standard of care.

Kalaris Therapeutics, Inc. (NASDAQ:KLRS) develops and commercializes treatments for prevalent retinal diseases.

1281292 - 11759070 - 1